The University of Chicago Header Logo

Connection

Ralph Weichselbaum to Cisplatin

Back to Details
This is a "connection" page, showing publications Ralph Weichselbaum has written about Cisplatin.
Ralph Weichselbaum
Connection Strength
1.043
Cisplatin
  1. Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells. Cancer Chemother Pharmacol. 2006 Dec; 58(6):765-70.
    View in: PubMed
    Score: 0.202
  2. Transcriptional control of viral gene therapy by cisplatin. J Clin Invest. 2002 Aug; 110(3):403-10.
    View in: PubMed
    Score: 0.157
  3. X-ray and cis-diamminedichloroplatinum(II) cross-resistance in human tumor cell lines. Cancer Res. 1988 Sep 15; 48(18):5133-5.
    View in: PubMed
    Score: 0.060
  4. A hot spot for RAD51C interactions revealed by a peptide that sensitizes cells to cisplatin. Cancer Res. 2004 May 01; 64(9):3002-5.
    View in: PubMed
    Score: 0.044
  5. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 2000 Aug 04; 275(31):23899-903.
    View in: PubMed
    Score: 0.034
  6. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
    View in: PubMed
    Score: 0.033
  7. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):70-6.
    View in: PubMed
    Score: 0.031
  8. The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol. 1995 Oct; 22(5 Suppl 12):8-12.
    View in: PubMed
    Score: 0.024
  9. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol. 1994 Nov; 12(11):2351-9.
    View in: PubMed
    Score: 0.023
  10. Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 1994 Aug 30; 30(1):151-60.
    View in: PubMed
    Score: 0.023
  11. Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):52-8.
    View in: PubMed
    Score: 0.021
  12. Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope. 1992 Jun; 102(6):630-6.
    View in: PubMed
    Score: 0.019
  13. cis-Diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. Cancer Res. 1992 Feb 15; 52(4):878-82.
    View in: PubMed
    Score: 0.019
  14. Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. Ann Oncol. 1992 Jan; 3(1):79-81.
    View in: PubMed
    Score: 0.019
  15. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer Chemother Pharmacol. 1992; 29(3):178-84.
    View in: PubMed
    Score: 0.019
  16. Radioresistant derivatives of radiosensitive CHO cells obtained following treatment with 5-azacytidine retain their sensitivity to cisplatin. Radiat Res. 1991 Aug; 127(2):226-9.
    View in: PubMed
    Score: 0.018
  17. Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. J Clin Oncol. 1991 Aug; 9(8):1376-84.
    View in: PubMed
    Score: 0.018
  18. Measurement of bioreduction rates of cells with distinct responses to ionizing radiation and cisplatin. Biochim Biophys Acta. 1991 Jul 10; 1093(2-3):121-4.
    View in: PubMed
    Score: 0.018
  19. Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report). Int J Radiat Oncol Biol Phys. 1991 Mar; 20(3):413-7.
    View in: PubMed
    Score: 0.018
  20. A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer. Cancer. 1990 Jul 15; 66(2):206-13.
    View in: PubMed
    Score: 0.017
  21. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1990 Feb; 8(2):241-7.
    View in: PubMed
    Score: 0.017
  22. A chemical compound that stimulates the human homologous recombination protein RAD51. Proc Natl Acad Sci U S A. 2008 Oct 14; 105(41):15848-53.
    View in: PubMed
    Score: 0.015
  23. Platinum complexes inhibit repair of potentially lethal damage following bleomycin treatment. Br J Cancer. 1987 Mar; 55(3):245-8.
    View in: PubMed
    Score: 0.013
  24. Combined modality treatment of head and neck cancer with cisplatin, bleomycin, methotrexate-leucovorin chemotherapy. Cancer. 1985 May 01; 55(9 Suppl):2149-55.
    View in: PubMed
    Score: 0.012
  25. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol. 2003 Apr; 14(4):564-9.
    View in: PubMed
    Score: 0.010
  26. Toxicity of aggressive multimodality therapy including cisplatinum, bleomycin and methotrexate with radiation and/or surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1982 May; 8(5):909-13.
    View in: PubMed
    Score: 0.010
  27. Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM). Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):787-91.
    View in: PubMed
    Score: 0.009
  28. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J. 2001 Mar-Apr; 7(2):140-8.
    View in: PubMed
    Score: 0.009
  29. Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage. Mol Cell Biol. 2000 Jul; 20(14):4979-89.
    View in: PubMed
    Score: 0.008
  30. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am. 1999 Jul-Aug; 5(4):219-23.
    View in: PubMed
    Score: 0.008
  31. Xrcc3 is required for assembly of Rad51 complexes in vivo. J Biol Chem. 1998 Aug 21; 273(34):21482-8.
    View in: PubMed
    Score: 0.007
  32. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol. 1998 Aug; 16(8):2715-21.
    View in: PubMed
    Score: 0.007
  33. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst. 1997 Feb 19; 89(4):308-13.
    View in: PubMed
    Score: 0.007
  34. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol. 1996 Nov; 7(9):913-8.
    View in: PubMed
    Score: 0.007
  35. Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms. J Biol Chem. 1996 Sep 27; 271(39):23775-9.
    View in: PubMed
    Score: 0.007
  36. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996 May; 14(5):1663-71.
    View in: PubMed
    Score: 0.006
  37. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature. 1995 Aug 31; 376(6543):785-8.
    View in: PubMed
    Score: 0.006
  38. Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1994 Apr 30; 29(1):153-62.
    View in: PubMed
    Score: 0.006
  39. Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy. Arch Otolaryngol Head Neck Surg. 1993 Jul; 119(7):743-6.
    View in: PubMed
    Score: 0.005
  40. Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience. J Urol. 1993 Apr; 149(4):753-7.
    View in: PubMed
    Score: 0.005
  41. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb; 11(2):360-8.
    View in: PubMed
    Score: 0.005
  42. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst. 1992 Jun 03; 84(11):877-82.
    View in: PubMed
    Score: 0.005
  43. Radioresistant derivatives of an X-ray-sensitive CHO cell line exhibit distinct patterns of sensitivity to DNA-damaging agents. Carcinogenesis. 1990 Aug; 11(8):1265-9.
    View in: PubMed
    Score: 0.004
  44. Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study. Chest. 1989 Jul; 96(1):110-3.
    View in: PubMed
    Score: 0.004
  45. Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer. J Clin Oncol. 1989 Jul; 7(7):838-45.
    View in: PubMed
    Score: 0.004
  46. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989 Mar 15; 63(6 Suppl):1048-53.
    View in: PubMed
    Score: 0.004
  47. A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer. 1989 Jan 01; 63(1):30-6.
    View in: PubMed
    Score: 0.004
  48. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol. 1988 Apr; 6(4):618-26.
    View in: PubMed
    Score: 0.004
  49. Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. NCI Monogr. 1988; (6):353-6.
    View in: PubMed
    Score: 0.004
  50. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1987 Jan; 5(1):10-20.
    View in: PubMed
    Score: 0.003
  51. Treatment complications after sequential combination chemotherapy and radiotherapy with or without surgery in previously untreated squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1985 Nov; 11(11):1887-93.
    View in: PubMed
    Score: 0.003
  52. Advanced squamous carcinoma of the head and neck. A preliminary report of neoadjuvant chemotherapy with cisplatin, bleomycin, and methotrexate. Arch Otolaryngol. 1984 Apr; 110(4):241-5.
    View in: PubMed
    Score: 0.003
  53. Chemotherapy for advanced carcinoma of the head and neck. A clinical update. Arch Otolaryngol. 1981 Apr; 107(4):237-41.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.